Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

Eye floaters are small, shadowy shapes that drift across your field of vision. While typically benign, they can be bothersome and impact visual clarity. Floaters result from changes in the vitreous humor, the gel-like substance filling the eye’s interior. For…

Autoimmune retinopathy (AIR) is a rare group of diseases characterized by retinal degeneration due to autoimmune mechanisms. There are two primary types of AIR: paraneoplastic retinopathy, associated with an underlying malignancy, and non-paraneoplastic autoimmune retinopathy (npAIR), which occurs independently of…

Vitritis is an ocular condition characterized by inflammation of the vitreous, a gel-like substance filling the eyeball behind the lens and in front of the retina. This inflammation can be due to various causes, including infections, autoimmune diseases, or trauma…

In the dynamic landscape of ophthalmology, the evaluation of tear production holds a central position in understanding and managing a spectrum of ocular conditions. Among the various tools available, Schirmer’s Test, named after the pioneering German ophthalmologist Otto Schirmer, stands…

What is Corneal Hysteresis? Corneal hysteresis is a measure of the cornea’s ability to absorb and dissipate energy when subjected to stress, such as the pressure exerted within the eye. The cornea is the clear, dome-shaped front surface of the…

EyeBio announced the successful completion of an extension to its Series A financing, resulting in a total raised amount of $130 million to date. The funding will be utilized by EyeBio to accelerate the company’s clinical development program and expand…

The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has issued a warning letter to e-commerce giant Amazon.com regarding the introduction of unapproved ophthalmic drug products into interstate commerce. The FDA’s warning, delivered in a…

Bayer announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a high-dose formulation of the renowned eye drug Eylea for the treatment of wet age-related macular degeneration and…

VSY Biotechnology GmbH is proud to announce the groundbreaking development of Varliciment, a revolutionary anti-VEGF agent for the treatment of age-related macular degeneration (AMD). Varliciment distinguishes itself from existing anti-VEGF agents like brolucizumab, namely Novartis’ Beovu, by being non-generic. This…

In a groundbreaking medical feat, a surgical team comprising more than 140 clinicians, including surgeons, nurses, and various healthcare professionals from New York University (NYU) Langone Health, has successfully conducted the world’s first whole-eye and partial face transplantation on a…